Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Accendra Health, Inc.NYSE: ACH
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt falls 17.1% from a year ago
Net debt stood at $1.83B at the end of Q1 FY2026, down 17.1% from a year earlier and down 6.0% from the prior quarter. Over 3 fiscal years it compounded at -10.5% a year.
Context
- Net debt amounted to 75.9% of total assets at the end of Q1 FY2026, up 30.4 pp from a year earlier.
- Net debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -17.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- 1.95B USD
- Year-over-year change
- -6.6%
- 4-year CAGR
- +15.5%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.95B | -6.6% |
| FY2024 | 2024-12-31 | 2.09B | -3.3% |
| FY2023 | 2023-12-31 | 2.16B | -20.6% |
| FY2022 | 2022-12-31 | 2.72B | +148.1% |
| FY2021 | 2021-12-31 | 1.1B | — |
Net Debt vs competitors
How ACH compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -17.1% is the 9th highest of 11, against a peer median of +21.6%.
- Net debt amounts to 75.9% of total assets for ACH, versus a peer median of 21.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.83B USD | -17.1% | -10.5% | 75.9% | |
| Mar 2026 | $71.05M USD | +219.5% | +30.2% | 28.5% | |
| Mar 2026 | $50.74M USD | +30.7% | -7.0% | 12.8% | |
| Mar 2026 | -$12.91M USD | +75.3% | — | 12.9% | |
| Apr 2026 | -CA$18.3M CAD | -163.7% | +31.5% | 5.3% | |
| Mar 2026 | -$26.68M USD | +4.3% | — | 13.4% | |
| Mar 2026 | -$43.2M USD | +36.8% | — | 39.4% | |
| Mar 2026 | -$51.67M USD | +52.0% | — | 34.6% | |
| Mar 2026 | -CA$85.97M CAD | -136.6% | — | 7.7% | |
| Mar 2026 | -$90.19M USD | +12.5% | — | 60.9% | |
BIOABioAge Labs, Inc. | Mar 2026 | -$237.74M USD | +3.8% | — | 59.8% |
| Peer median (excluding ACH) | — | +21.6% | +30.2% | 21.0% | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 55.71M | 69.47M | 243.04M | 49.38M | 281.99M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 681.56M | 763.5M | 598.26M | 690.24M | 95.91M |
| Inventory | 1.5B | 1.33B | 1.11B | 1.13B | 74.44M |
| Other Current Assets | 88.56M | 128.64M | 150.89M | 149.52M | 95.54M |
| Total Current Assets | 2.32B | 2.3B | 2.1B | 2.02B | 547.87M |
| Property, Plant & Equipment (Net) | 511.24M | 858.93M | 840.51M | 864.97M | 365.26M |
| Goodwill | 390.19M | 1.64B | 1.64B | 1.33B | 1.23B |
| Intangible Assets | 243.75M | 483.74M | 361.84M | 296.73M | 136.47M |
| Long-term Investments | 16.32M | 15.46M | 8.45M | 6.11M | 1.34M |
| Tax Assets | 0 | 0 | (8.45M) | 0 | 0 |
| Other Non-current Assets | 53.25M | 96.26M | 149.35M | 134.05M | 172.69M |
| Total Non-current Assets | 1.21B | 3.09B | 2.99B | 2.63B | 1.9B |
| Total Assets | 3.54B | 5.39B | 5.09B | 4.66B | 2.45B |
| Account Payables | 1B | 1.15B | 1.17B | 1.25B | 363.57M |
| Short-term Debt | 43.85M | 15.38M | 204.08M | 40M | 293.27M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 116.4M | 0 | 0 |
| Other Current Liabilities | 182.35M | 227.44M | 191.66M | 425.54M | 220.81M |
| Total Current Liabilities | 1.34B | 1.57B | 1.89B | 1.87B | 947.08M |
| Long-term Debt | 936.23M | 2.47B | 1.88B | 1.8B | 1.87B |
| Deferred Tax Liabilities | 35.31M | 60.83M | 41.65M | 22.46M | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 108.94M | 114.94M | 122.59M | 100.13M | 25.15M |
| Total Non-current Liabilities | 1.25B | 2.87B | 2.28B | 2.22B | 1.97B |
| Total Liabilities | 2.6B | 4.44B | 4.17B | 4.09B | 2.91B |
| Common Stock | 150.87M | 152.56M | 153.09M | 154.4M | 152.78M |
| Retained Earnings | 387.62M | 410.01M | 368.71M | 6.02M | (1.08B) |
| Accumulated OCI | (40.59M) | (35.85M) | (31.82M) | (49.34M) | (885K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 938.5M | 945.6M | 924.17M | 565.23M | (460.98M) |
| Total Debt | 1.15B | 2.79B | 2.41B | 2.14B | 2.23B |
| Net Debt | 1.1B | 2.72B | 2.16B | 2.09B | 1.95B |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.